Wright Medical/Orthomet
This article was originally published in The Gray Sheet
Executive Summary
Wright Medical Technology extends until Nov. 30 its offer to purchase outstanding shares of Orthomet for $11 per share of common stock and $12.09 per share of 6% convertible preferred stock. Wright is gathering information requested by the Federal Trade Commission under the Hart-Scott-Rodino anti-trust law and "is continuing to use its best efforts to provide the requested information as promptly as possible," the company says. Wright and Orthomet reached a definitive merger agreement in late October ("The Gray Sheet" Oct. 24, "In Brief")
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.